BRIEF-U.S. FDA extends review period for Baricitinib, an investigational rheumatoid arthritis treatment By: Reuters: Company News January 13, 2017 at 16:56 PM EST * U.S. FDA extends review period for baricitinib, an investigational rheumatoid arthritis treatment Read More >> Related Stocks: Eli Lilly Incyte Corp